Skip to main content
. 2023 Sep 25;128(12):1460–1471. doi: 10.1007/s11547-023-01726-2

Table 2.

Comparison of baseline data of CT features in training set, testing set and verification set (%)

Features Training set (n = 78) Testing set (n = 32) Validation set (n = 33) P
Tumor size > 5 cm 39(50) 16(50) 21(63.64) 0.388
≤ 5 cm 39(50) 16(50) 12(36.36)
Peritumoral satellite lesions No 66(84.62) 26(81.25) 24(72.73) 0.343
Yes 12(15.38) 6(18.75) 9(27.27)
Tumor margin Unsmooth 62(79.49) 24(75) 31(93.94) 0.103
Smooth 16(20.51) 8(25) 2(6.06)
Tumor capsule None 49(62.82) 24(75) 29(87.88) 0.086
Smooth 7(8.97) 2(6.25) 0(0)
Unsmooth 22(28.21) 6(18.75) 4(12.12)
Intratumoral necrosis None 20(25.64) 11(34.38) 5(15.15) 0.305
< 25% 30(38.46) 11(34.38) 12(36.36)
25–50% 21(26.92) 6(18.75) 9(27.27)
51–75% 2(2.56) 3(9.38) 5(15.15)
> 75% 5(6.41) 1(3.13) 2(6.06)
Bile duct dilatation No 67(85.9) 29(90.63) 22(66.67) 0.020*
Yes 11(14.1) 3(9.38) 11(33.33)
Enhancement mode Wash in and wash out 21(26.92) 8(25) 9(27.27) 0.799
Inhomogeneous enhancement 51(65.38) 19(59.38) 21(63.64)
Persistent enhancement 6(7.69) 5(15.63) 3(9.09)
Peritumoral enhancement in arterial phase Yes 28(35.9) 11(34.38) 14(42.42) 0.759
No 50(64.1) 21(65.63) 19(57.58)
Large vein invasion No 63(80.77) 27(84.38) 19(57.58) 0.015*
Yes 15(19.23) 5(15.63) 14(42.42)
Lymph node enlargement No 65(83.33) 30(93.75) 19(57.58) 0.001*
Yes 13(16.67) 2(6.25) 14(42.42)

*represents P < 0.05